Written by Emil Luca: The new Aristotle multi-cancer test is a blood test that can detect the molecular signatures of multiple cancers from a single sample of blood. It is intended to help find cancer earlier.
Aristotle multi-cancer test was developed, and its performance characteristics determined by Stage Zero Life Sciences, Ltd., (Richmond, VA). It has not been cleared or approved by the US Food and Drug Administration. This test must be ordered by and used only in consultation with a healthcare provider.
Aristotle® is a multi-cancer test panel that uses mRNA technology to simultaneously detect multiple cancer signatures from a single sample of blood. It screens for the molecular signatures associated with multiple, individual cancers, including breast, ovarian, endometrial, colorectal, liver, stomach, prostate, and others.
The underlying mRNA technology, The Sentinel Principle, has been validated in more than 9,000 patients and used by more than 100,000 patients in North America. Aristotle was selected for online publication at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO):
Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, and Burakoff R; Journal of Clinical Oncology 2020; 38:15_suppl, e15037-e15037
This article shows that at a specificity of 99%, the test has a sensitivity ranging from 55.6% for colon cancer to 100% for cervical and stomach cancers.
The early diagnosis of cancer cannot be overemphasized. The earlier the cancer is detected, the higher chance of survival of the patient. That is why screening tests like this one should always be sought, hoping for complete cure before it is too late.
Cancer Blood Tests Revolutionize Oncology
The writer declares no conflict of interest. Specific information about this product are obtained from the manufacturer’s website. Inquiries are to be addressed to the manufacturer.